p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study - Wikidata - awgldk - TriplyDB

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study

http://www.wikidata.org/entity/Q36115950

about

Chemoresistance in human ovarian cancer: the role of apoptotic regulators "Ziziphus jujuba": A red fruit with promising anticancer activities Chemoresistance and targeted therapies in ovarian and endometrial cancers TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner.p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.The p53 tumour suppressor protein.P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients.Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas Evaluation of FHIT gene alterations in ovarian cancer HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.p53 and disease: when the guardian angel fails.Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2 TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival.Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes.Transcriptome profiling identifies genes and pathways deregulated upon floxuridine treatment in colorectal cancer cells harboring GOF mutant p53.Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.Oligodendrocyte/type-2 astrocyte progenitor cells and glial-restricted precursor cells generate different tumor phenotypes in response to the identical oncogenes.The role of Tau protein in resistance to paclitaxel.Metabolic approaches to overcoming chemoresistance in ovarian cancer.Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells.Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis.Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer.Improved survival in women with BRCA-associated ovarian carcinoma.Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs.Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer.

P2860

Q24791433-5B3AC286-E196-47AC-8E2A-BFA8FB95C04F Q26782533-FE1B932E-AB24-4B5E-A7A8-36D61AB91D8B Q28073246-3C9E438B-66FE-4E0D-AEA2-7E73848417F1 Q33317044-563E382D-88A8-41A7-B4E0-3490C6C21FAB Q33633387-92A4A14E-B253-46AD-9FA4-A3E4A9921B5D Q33930946-550C5977-4E76-474A-929E-E6CC912E00AC Q33953631-54C9293C-20D8-434A-BD59-ADBCD3687BDB Q34187832-6553EA70-1B1F-43D5-A146-8A97616E2C10 Q34667912-FDE0A0A1-2CA7-4F47-9D66-AEC9158ABE13 Q35119058-ED8696D5-FF7E-455C-9160-5E6B2FAF0B60 Q36114881-EC308241-BB3A-44EE-B97D-91F911327194 Q36115202-24593AD1-9874-4801-B06E-FEAD9232E03C Q36211422-E771D3F6-219B-44B0-806F-224B47334A7D Q36292325-5CEBA460-2308-466A-85EB-C8EF71300A85 Q36323374-B64B1857-B58B-4FF8-B3AF-10997F68C6F3 Q36430165-F2A8D1D8-52D3-4381-804C-DA531EB69B28 Q36612301-B864B979-21F6-47AB-A1A6-93849F0EE1DE Q36619706-41B065D1-9D60-441E-84FA-E55637F47A66 Q36621114-994DA8F1-4EC1-43CD-911B-38C21415D670 Q36643987-BF5EF66E-B5D0-46E2-9975-2C456D8C5B7E Q36696616-F58CA7A1-1923-42B0-84F3-BFADFCEDE817 Q36798420-DD5F98A4-83DF-4AED-941B-B97E07683BF6 Q36799102-76411789-4F57-4C5B-AAE4-B9F16EB68FAE Q36984707-2A0164E5-E628-40C6-8595-8A76AB0F8887 Q37231529-ACBA95B2-FB1B-40F9-81F3-00CA966A5793 Q37895519-8E5ECD6D-6D21-4DCF-B219-AC2AFC44022F Q37906707-DEF347AA-6DD5-493E-A763-D1DC8469ABD0 Q39791587-66293D62-D13F-492C-B207-8FEBBE3F570C Q40214416-48BD789E-CAB3-4A45-8CB7-741880955742 Q40773843-5DD56E85-5876-413F-969B-79828069DC07 Q40788757-4D815866-E1A9-417A-9DB7-87899D1A3CC0 Q40811131-6489A602-4D9D-4E71-B4EB-373B7316508B Q43797874-FC72F0EB-90D7-49BA-AFBE-015340EC0125 Q46546357-FC560825-7D13-48FD-97E9-5312794D237C Q46693199-32683B02-FE0F-4929-9CEB-D1495EBC1E64 Q48018005-D399186B-A00D-456D-AC97-DD448A500A23 Q53631419-8360C19D-A7C6-4287-9E42-03436EB427B7 Q54040780-2772CD48-29AB-4121-8AFA-7A50000D8090

P2860

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study

http://www.wikidata.org/entity/Q36115950

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

1997年论文

@zh

1997年论文

@zh-cn

name

p53 alterations are predictive ...... and immunohistochemical study

@ast

p53 alterations are predictive ...... and immunohistochemical study

@en

type

label

p53 alterations are predictive ...... and immunohistochemical study

@ast

p53 alterations are predictive ...... and immunohistochemical study

@en

prefLabel

p53 alterations are predictive ...... and immunohistochemical study

@ast

p53 alterations are predictive ...... and immunohistochemical study

@en

P1433

Q36115950-AE5F1BAA-E4D7-4EE8-87FA-A84C36A03E84

P1476

Q36115950-CCDF2A3E-E4F0-42CB-8FB0-D3ADFC011195

P2093

Q36115950-07552869-C6B7-4FA7-99AB-6129308FBDE4

Q36115950-125DE262-647A-4FC4-901A-EA3861D6369F

Q36115950-5286B4F4-4007-49E2-9827-D31B03979F0D

Q36115950-54E9842E-12D7-440D-B9CA-7EC45CBB166B

Q36115950-76EE6374-749F-40FE-9699-E394A401C06D

Q36115950-7AD716A5-1215-4791-B5C0-F94A5A9CAADB

Q36115950-9F07C0C1-2872-43A3-82A9-916512DDB749

Q36115950-C2480BB9-A725-42BB-B866-76531D8FDA71

Q36115950-C6A03DAC-4FFC-487C-BC24-3264D5D632EF

Q36115950-EBF7228F-4202-4F18-A59C-B7C2439AB1FF

P2860

Q36115950-14E7AB8C-6D92-4070-B719-EBD1D7B273D1

Q36115950-189D58CD-B7C4-4FCD-823C-FB3F73A708A1

Q36115950-26B86110-8783-4DA1-BB1D-F3F61A21004D

Q36115950-29555645-72F4-4730-99C0-C8313801F2E5

Q36115950-2E16D1D6-29F7-4AED-90AB-E6DDA91FAA4B

Q36115950-2EEB3345-F676-4EC9-822F-C2024536B53B

Q36115950-32B5E9EB-6F45-44B3-8BC6-DA2268592BC6

Q36115950-32D0B2FC-8396-4344-951A-EAE8D230EC2B

Q36115950-37DA57EF-CC53-4D0D-AEF0-B66AF19DA504

Q36115950-3C9E1586-D7B5-4D16-9D7A-B99DA3CEE5A7

P2888

Q36115950-38738406-C1C6-4FC6-ADCC-D06F605E2313

P304

Q36115950-BDB7507C-B55E-43BF-8461-785FA329288A

P31

Q36115950-3F632DEA-FAEF-4749-B421-33F6E9EFECD0

P356

Q36115950-538535F4-E586-4F39-958E-AFB923B9B383

P407

Q36115950-0E59ED74-709B-430F-B99C-39C97A19E308

P433

Q36115950-29615BC2-A7CB-4ABC-AB33-C3EB1261D6EA

P478

Q36115950-3FFC92D7-00C2-4BB6-9D08-D7F3BC2400AF

P577

Q36115950-ACE0C3D3-953C-4137-8FC3-CA7E58DF7574

P5875

Q36115950-0BA677FF-1116-4B55-B32C-0CA5C85948FA

P698

Q36115950-591FA9A8-1CCC-41F6-B072-91EEDA6D1FF8

P932

Q36115950-C9829C32-F5AF-47F1-8ED2-DE8291797904

P356

P1433

British Journal of Cancer

P1476

p53 alterations are predictive ...... and immunohistochemical study

@en

P2093

Bevilacqua G

http://www.w3.org/2001/XMLSchema#string

Buttitta F

http://www.w3.org/2001/XMLSchema#string

Carnicelli V

http://www.w3.org/2001/XMLSchema#string

Cosio S

http://www.w3.org/2001/XMLSchema#string

Gadducci A

http://www.w3.org/2001/XMLSchema#string

Gagetti O

http://www.w3.org/2001/XMLSchema#string

Genazzani AR

http://www.w3.org/2001/XMLSchema#string

Marchetti A

http://www.w3.org/2001/XMLSchema#string

Morganti M

http://www.w3.org/2001/XMLSchema#string

Pellegrini S

http://www.w3.org/2001/XMLSchema#string

P2860

Apoptosis, oncosis, and necrosis. An overview of cell death

Apoptosis in the pathogenesis and treatment of disease

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction

p53 is required for radiation-induced apoptosis in mouse thymocytes

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.

The role of apoptosis in cell killing by cisplatin: a flow cytometric study.

Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma.

Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.

P2888

P304

230-235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1997.38

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

1997-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14198694

http://www.w3.org/2001/XMLSchema#string

P698

9010031

http://www.w3.org/2001/XMLSchema#string

P932

2063269

http://www.w3.org/2001/XMLSchema#string